PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC)
| Autor: | Qendri, V., May, J., Malcolm, B., Ejzykowicz, F., Kurt, M., Cakar, E., Klijn, S. |
|---|---|
| Zdroj: | In Value in Health December 2020 23 Supplement 2:S521-S521 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect